Metformin and risk of hepatocellular carcinoma: are statins the missing link? | Gut

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article info

PostScript

Letter

Metformin and risk of hepatocellular carcinoma: are statins the missing link?

Authors

Siddharth Singh Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Preet Paul Singh Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles

Correspondence to
Dr Siddharth Singh, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA; singh.siddharth2{at}mayo.edu

Citation

Singh S, Singh PP

Metformin and risk of hepatocellular carcinoma: are statins the missing link?

Gut 2013;62:951-952.

Publication history

Received November 28, 2012
Accepted November 28, 2012
First published December 22, 2012.

Online issue publication

April 18, 2016

Article Versions

Previous version (18 April 2016).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions